Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients

Roberto Baldelli, Elisabetta Ferretti, Marie Lise Jaffrain-Rea, Gianluca Iacobellis, Giuseppe Minniti, Barbara Caracciolo, Carlo Moroni, Rosario Cassone, Alberto Gulino, Guido Tamburrano

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.

Original languageEnglish
Pages (from-to)527-532
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume84
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Acromegaly
Somatostatin
Insulin-Like Growth Factor I
Left Ventricular Hypertrophy
Life Expectancy
Left Ventricular Function
Relaxation time
Therapeutics
Morbidity
Plasmas
Mortality
lanreotide

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Baldelli, R., Ferretti, E., Jaffrain-Rea, M. L., Iacobellis, G., Minniti, G., Caracciolo, B., ... Tamburrano, G. (1999). Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. Journal of Clinical Endocrinology and Metabolism, 84(2), 527-532. https://doi.org/10.1210/jc.84.2.527

Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. / Baldelli, Roberto; Ferretti, Elisabetta; Jaffrain-Rea, Marie Lise; Iacobellis, Gianluca; Minniti, Giuseppe; Caracciolo, Barbara; Moroni, Carlo; Cassone, Rosario; Gulino, Alberto; Tamburrano, Guido.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 84, No. 2, 1999, p. 527-532.

Research output: Contribution to journalArticle

Baldelli, R, Ferretti, E, Jaffrain-Rea, ML, Iacobellis, G, Minniti, G, Caracciolo, B, Moroni, C, Cassone, R, Gulino, A & Tamburrano, G 1999, 'Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients', Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 2, pp. 527-532. https://doi.org/10.1210/jc.84.2.527
Baldelli, Roberto ; Ferretti, Elisabetta ; Jaffrain-Rea, Marie Lise ; Iacobellis, Gianluca ; Minniti, Giuseppe ; Caracciolo, Barbara ; Moroni, Carlo ; Cassone, Rosario ; Gulino, Alberto ; Tamburrano, Guido. / Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. In: Journal of Clinical Endocrinology and Metabolism. 1999 ; Vol. 84, No. 2. pp. 527-532.
@article{30342875dbfd499a84bf31286d527b8f,
title = "Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients",
abstract = "Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.",
author = "Roberto Baldelli and Elisabetta Ferretti and Jaffrain-Rea, {Marie Lise} and Gianluca Iacobellis and Giuseppe Minniti and Barbara Caracciolo and Carlo Moroni and Rosario Cassone and Alberto Gulino and Guido Tamburrano",
year = "1999",
doi = "10.1210/jc.84.2.527",
language = "English",
volume = "84",
pages = "527--532",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients

AU - Baldelli, Roberto

AU - Ferretti, Elisabetta

AU - Jaffrain-Rea, Marie Lise

AU - Iacobellis, Gianluca

AU - Minniti, Giuseppe

AU - Caracciolo, Barbara

AU - Moroni, Carlo

AU - Cassone, Rosario

AU - Gulino, Alberto

AU - Tamburrano, Guido

PY - 1999

Y1 - 1999

N2 - Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.

AB - Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.

UR - http://www.scopus.com/inward/record.url?scp=0033054602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033054602&partnerID=8YFLogxK

U2 - 10.1210/jc.84.2.527

DO - 10.1210/jc.84.2.527

M3 - Article

C2 - 10022411

AN - SCOPUS:0033054602

VL - 84

SP - 527

EP - 532

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -